ADCs represent complex biologics combing a targeting antibody molecule with a cytotoxic warhead via a linker system. The design of the linker systems is crucial to ensure the warhead is only released at the target site, whilst enabling conjugation to an active site on the protein.

Mass spectrometry can be utilized in various modalities to monitor loss of payloads when incubated in plasma providing a rapid measurement of relative stability. This webinar will detail how mass spectrometry is used in ADC development and how the X500B QTOF system represents a versatile platform for measurement of intact, reduced, and digested proteins.